Skip to main content

Table 1 Studies and cases descriptive characteristics

From: Autologous bone graft in the treatment of post-traumatic bone defects: a systematic review and meta-analysis

Authors

Year

Treatment period

Study type

LE

(n)

Age (y) [range]

Male/female

Bone defect location (femur/tibia/humerus/foream/other bones)

FU (mts)

Ring et al. [16]

2000

nr

R-CS

IV

15

48 [22 - 80]

9/6

-/-/15/-/-

31

Tu et al. [17]

2001

1990–1993

R-CS

IV

48

48 [15 - 62]

40/8

10/32/2/4/-

72

Toh et al. [18]

2001

1983–1998

R-CS

IV

19

53 [21 - 84]

17/2

-/19/-/-/-

98

Heitmann et al. [19]

2002

nr

R-CS

IV

12

43 [16 - 79]

7/5

-/-/12/-/-

tn

Muramatsu et al. [20]

2003

1985–2000

R-CS

IV

13

51 [27 - 80]

6/7

-/-/13/-/-

tn

Pelissier et al. [15]

2003

1984–1999

R(C)-CS

IV

40

tn

tn

tn

tn

Yajima et al. [21]

2004

1976–2000

R-CS

IV

20

37 [17 - 73]

16/4

9/8/-/2/1

64

Lee et al. [22]

2004

1982–2001

R-CS

IV

51

41 [15 - 66]

48/3

-/51/-/-/-

nr

Adani et al. [23]

2004

1993–2000

R-CS

IV

11

38 [16 - 65]

5/6

-/-/-/11/-

tn

Ring et al. [24]

2004

1983–2001

R-CS

IV

35

40 [21 - 66]

18/17

-/-/-/35/-

43

Yazar et al. [25]

2004

1993–2000

R-CS

IV

61

37.5 [10 - 82]

42/19

7/49/-/-/6

58

Safoury [26]

2005

nr

R-CS

IV

18

34 [22 - 46]

16/2

-/-/-/18/-

36

Jones et al. [27]

2006

2000–2003

RCT

II

15

38 [18 - 71]

13/2

-/15/-/-/-

tn

El-Sayed et al. [28]

2007

nr

R-CS

IV

12

25 [12 - 40]

11/1

-/8/2/2/-

24

Ristiniemi et al. [29]

2007

2000–2004

R-CS

IV

23

35 [14 - 75]

16/7

-/23/-/-/-

nr

Adani et al. [30]

2008

1994–2004

R-CS

IV

13

37 [21 - 62]

10/3

-/-/13/-/-

nr

El-Gammal et al. [48]

2008

1995–2004

R(C)-CS

IV

13

31.5 [nr]

11/2

-/13/-/-/-

38

Ryzewicz et al. [31]

2009

1998–2007

R(C)-CS

IV

18

34.2 [18 - 51]

11/7

-/18/-/-/-

nr

Allende et al. [32]

2009

1996–2008

R-CS

IV

10

32.8 [11 - 56]

9/1

-/-/4/6/-

tn

Cavadas et al. [33]

2010

2000–2008

R-CS

IV

41

nr [17 - 64]

39/2

-/41/-/-/-

nr

McCall et al. [34]

2010

2003–2007

P-CS

IV

21

30.6 [nr]

13/8

5/15/-/1/-

nr

Sun et al. [35]

2010

2005–2007

R-CS

IV

10

31 [16 - 50]

9/1

3/7/-/-/-

26

Apard et al. [36]

2010

nr

R-CS

IV

12

40.6 [18 - 74]

10/2

-/12/-/-/-

39

Zhen et al. [37]

2010

2000–2007

R-CS

IV

28

31.5 [17 - 56]

21/7

-/28/-/-/-

36

Chai et al. [38]

2010

2005–2007

R-CS

IV

16

31 [16 - 50]

10/6

-/9/-/4/3

18

Georgescu et al. [39]

2011

1997–2007

R-CS

IV

44

30.5 [5 - 66]

33/11

3/22/5/3/11

23

Chung et al. [40]

2011

1989–2007

R-CS

IV

10

25.3 [16 - 43]

8/2

-/10/-/-/-

41

Niu et al. [41]

2011

2003–2008

R-CS

IV

19

38.9 [18 - 61]

12/7

8/11/-/-/-

nr

Liang et al. [42]

2012

1996–2006

R-CS

IV

16

33.3 [21 - 46]

nr

16/-/-/-/-

83

Gulan et al. [43]

2012

1991–1998

R-CS

IV

10

30 [22 - 51]

10/0

-/10/-/-/-

144

Liang et al. [44]

2012

2001–2007

R-CS

IV

14

34.3 [23 - 48]

11/3

14/-/-/-/-

67

Gao et al. [45]

2012

2004–2006

R-CS

IV

18

34 [16 - 56]

13/5

7/11/-/-/-

40

Niu et al. [46]

2012

1993–2008

R-CS

IV

22

33.8 [17 – 60]

14/8

-/-/22/-/-

39

Özaksar et al. [47]

2012

1993–2009

R-CS

IV

21

32 [16 - 47]

19/2

-/21/-/-/-

74

  1. LE level of evidence, n number of patients included in this review, y years, mts months, FU follow-up, R retrospective, P prospective, CS case series, C controlled, RCT randomized controlled trial, nr not reported, tn technical note (see Additional file 3)